BridgeBio Pharma Stock: Set New Commercial Launches After Trial Successes (NASDAQ:BBIO)

BridgeBio ( BBIO ) has risen roughly 90% since I initiated coverage back in April of 2025. It quickly became the largest position in my portfolio and was the primary driver of my outperformanceLike millions of other investors, I got Robinhood and started trading during the pandemic. Unlike most of those investors, I carefully studied hundreds of earnings reports for clues to future performance, and I was able to identify many future winners, such as OPRX, OTRK, FUBO, and PLUG. My style of investing is ident ...